Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedDec 11, 2019fentaNYL 2750 mcg/55 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0558-2020Class IITerminatedDec 11, 2019fentaNYL 200 mcg/100 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0557-2020Class IITerminatedDec 11, 2019fentaNYL 100 mcg/2 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0556-2020Class IITerminatedDec 11, 2019fentaNYL 1000 mcg/100 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0555-2020Class IITerminatedDec 11, 2019fentaNYL 400 mcg/200 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0554-2020Class IITerminatedDec 11, 2019fentaNYL 2500 mcg/250 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0553-2020Class IITerminatedDec 11, 2019fentaNYL 500 mcg/250 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0552-2020Class IITerminatedDec 11, 2019fentaNYL 1500 mcg/30 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0551-2020Class IITerminatedDec 11, 2019fentaNYL 200 mcg/100 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0550-2020Class IITerminatedDec 11, 2019fentaNYL 500 mcg/250 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0549-2020Class IITerminatedDec 11, 2019fentaNYL 200 mcg/100 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0548-2020Class IITerminatedDec 11, 2019fentaNYL 500 mcg/250 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0547-2020Class IITerminatedDec 11, 2019fentaNYL 500 mcg/250 mLPresence of Particulate matter: manufacturer recalled fentanyl API due to potential for glass particulesQuVa Pharma, Inc. · D-0546-2020Class IIOngoingDec 11, 2019Zantac 75 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0545-2020Class IIOngoingDec 11, 2019Zantac 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0544-2020Class IIOngoingDec 11, 2019Regular Strength Zantac 75 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0543-2020Class IIOngoingDec 11, 2019Regular Strength Zantac 75 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0542-2020Class IIOngoingDec 11, 2019Regular Strength Zantac 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0541-2020Class IIOngoingDec 11, 2019Regular Strength Zantac 75 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0540-2020Class IIOngoingDec 11, 2019Maximum Strength Zantac 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0539-2020Class IIOngoingDec 11, 2019Cool Mint Maximum Strength Zantac 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0538-2020Class IIOngoingDec 11, 2019Regular Strength Zantac 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0537-2020Class IIOngoingDec 11, 2019Maximum Strength Zantac 150 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0536-2020Class IIOngoingDec 11, 2019Regular Strength Zantac 75 mgCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0535-2020Class IIOngoingDec 11, 2019Cool Mint Tablets Maximum Strength Zantac 150 mg SanofiCGMP Deviations: Presence of NDMA impurity detected in product.Sanofi-Aventis U.S. LLC · D-0534-2020Class IITerminatedDec 11, 2019LETS GEL KIT Convenience PackMicrobial contamination of non-sterile product.Fagron, Inc · D-0533-2020Class IITerminatedDec 4, 2019Potassium PhosphateFailed Stability Specifications: Product exceeds compendia and firm's specifications for iron content.Avantor Performance Materials Inc · D-0575-2020Class IITerminatedDec 4, 2019Lidocaine HCl InjectionPresence of Foreign Substance: Foreign material found inside the vial.AuroMedics Pharma LLC · D-0573-2020Class IITerminatedDec 4, 2019Ibuprofen Oral Suspension USPPresence of foreign substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.Preferred Pharmaceuticals, Inc · D-0531-2020Class IIOngoingDec 4, 2019Aurobindo Ranitidine Capsules 150 mgCGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.AuroMedics Pharma LLC · D-0530-2020Class IIOngoingDec 4, 2019Ranitidine SyrupCGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.AuroMedics Pharma LLC · D-0529-2020Class IIOngoingDec 4, 2019Aurobindo Ranitidine Capsules 300 mgCGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.AuroMedics Pharma LLC · D-0528-2020Class IIOngoingDec 4, 2019Aurobindo Ranitidine Caspules 150 mgCGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.AuroMedics Pharma LLC · D-0527-2020Class IIOngoingDec 4, 2019DG Health Acid Reducer Ranitidine Tablets 150 mgCGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.AuroMedics Pharma LLC · D-0526-2020Class IITerminatedDec 4, 2019AVKARE Ranitidine TabletsCGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIAVKARE Inc. · D-0525-2020Class IITerminatedDec 4, 2019AVKARE Ranitidine TabletsCGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIAVKARE Inc. · D-0524-2020Class IITerminatedDec 4, 2019Testosterone Cypionate 180 mg/mL/Testosterone Propionate 20mg/mL Oil Injection SolutionLack of sterility assurance.New Vitalis Pharmacy LLC dba New Vitalis Pharmacy · D-0523-2020Class IIITerminatedDec 4, 2019Amiodarone Hydrochloride InjectionCrystallization: Presence of visible particulate matter.AuroMedics Pharma LLC · D-0522-2020Class IIITerminatedDec 4, 2019Amiodarone Hydrochloride InjectionCrystallization: Presence of visible particulate matter.AuroMedics Pharma LLC · D-0521-2020Class IIITerminatedDec 4, 2019Amiodarone Hydrochloride InjectionCrystallization: Presence of visible particulate matter.AuroMedics Pharma LLC · D-0520-2020